

**Cancer Prevention and Control CIRB Meeting Agenda**

**May 25, 2023**

---

**I. Amendment ReReview**

**URCC-18110CD**, Implementing Palliative Care: Learning Collaborative vs. Technical Assistance (Version Date 05/15/23)

---

**II. Amendment**

**S1912CD**, A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) (Version Date 04/07/23)

---

**III. New Study - Initial Review**

**NWU22-12-01**, A phase 2 placebo-controlled trial of Urolithin A supplementation in men with prostate cancer undergoing radical prostatectomy (Version Date 04/20/23)

---

**IV. New Study - Initial Review**

**UMI22-09-01**, Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer (Version Date 04/24/23)

---

**V. Amendment**

**A212102**, Blinded Reference Set for Multicancer Early Detection Blood Tests (Version Date 04/11/23)

---

**VI. Amendment**

**UAZ20-01-01**, Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy (Version Date 04/04/23)

---

**VII. Amendment**

**WF-1805CD**, Implementation and Effectiveness Trial of HN-STAR (Version Date 01/09/23)

---

**VIII. Continuing Review**

**MDA20-02-01**, Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A randomized, Phase IIb, Window of Opportunity Presurgical Trial. (Version Date 07/15/22)

---

**IX. Continuing Review**

**NRG-CC008**, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK] (Version Date 07/29/22)

---

**X. Continuing Review**

**NWU20-02-01**, Surgical Window of Opportunity Study of Megestrol Acetate Compared with Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia (Version Date 05/02/23)

---

**XI. Continuing Review**

**NWU20-02-02**, A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 By Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer (Version Date 11/17/22)

---

**XII. Continuing Review**

**UWI20-00-01**, A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Participants with Early Stage Triple Negative Breast Cancer (Version Date 02/15/23)

---